Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug safety
Biotech
After 2 undisclosed deaths, can China’s IIT still be trusted?
Seeing the deaths as proof that the investigator-initiated trials (IIT) pathway is unreliable ignores new guardrails added by China, experts told Fierce.
Angus Liu
,
Darren Incorvaia
Aug 17, 2026 7:20am
Abivax stock suffers as cancer cases overshadow stellar efficacy
Jun 2, 2026 5:30am
New cancer cases prompt Kyowa to shutter rocatinlimab trials
Mar 3, 2026 11:00am
FDA to ‘carefully shepherd’ CAR-T for autoimmune disease: Prasad
Feb 3, 2026 11:40am
CalciMedica stock craters as trial stopped over 'safety concern'
Jan 28, 2026 8:40am
Sarepta shares safety update on DM1 RNA med
Nov 24, 2025 4:00pm
